Global pharmaceutical company Allergan has announced key future growth drivers for its medical aesthetics portfolio at its first ever Medical Aesthetics Analyst Day this month.
A clinical study conducted by global pharmaceutical company Allergan suggests that higher doses of Botox Cosmetic (onabotulinumtoxinA) to treat moderate to severe glabella lines produces greater duration of treatment effect.
Allergan recently unveiled new data from a multicenter, randomised, double-blind trial that showed 20 Units of VISTABEL® was as effective as 30 Units of Bocouture® for the treatment of moderate to severe glabellar lines. The study results were presented during the 7th European Masters in Anti-Ageing Medicine (EMAA) congress in Paris. “This new study underlines why it is important that medical aesthetic practitioners are aware of the differences between each of the botulinum toxins when selecting the most appropriate treatment for their patients,” comments Dr Moers-Carpi from Munich, Germany and lead investigator for the study. “With botulinum toxin manufacturers each having unique definitions of a unit, aesthetic practitioners should be vigilant in adopting the treatment protocol set by the respective manufacturer and not translating previous experience with one toxin to another.”
Global pharmaceutical company Allergan has announced plans to invest more than €42 million (over £36 million) in an expansion.
New technology will be in place from January 31 to monitor advertisements on social media relating to the promotion of prescription-only medicines (POMs) such as botulinum toxin.
Allergan's $2.4 billion dollar deal to acquire medical and cooling technology company ZELTIQ Aesthetics has successfully been completed, according to an announcement by the global pharmaceutical company.
Aesthetic support Allergan Spark will host a Spark Talks event on July 22, during which aesthetic practitioners will give 15-minute talks from a virtual TV studio.
UK aesthetic distributor Schuco Aesthetics has relocated its premises from Watford to Leavesden Park.
Global pharmaceutical company Allergan has announced that it will acquire US-based biotechnology company Bonti.
Pharmaceutical company mesoestetic has launched a new online training programme for aesthetic practitioners.